Head and neck squamous cell carcinoma (HNSCC) is a diverse group of cancers originating from the mucosal linings of the oral cavity, oropharynx,...
Vous n'êtes pas connecté
Immutep (IMMP) jumps 15% on positive results from a late-stage study evaluating its candidate, efti, in combination with Keytruda to treat first-line head and neck squamous cell carcinoma patients.
Head and neck squamous cell carcinoma (HNSCC) is a diverse group of cancers originating from the mucosal linings of the oral cavity, oropharynx,...
Cancer is a complex disease characterized by uncontrolled cell growth, significantly impacting global health. Head and neck cancers rank as the sixth...
BRISBANE, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing...
This approval is based on late-stage study data, which shows that treatment with AstraZeneca's (AZN) Imfinzi reduced the risk of recurrence by 32% in...
The approval is based on late-stage study data wherein treatment with J&J's (JNJ) Rybrevant plus Lazcluze cut the risk of disease progression or...
RAHWAY, N.J.--(BUSINESS WIRE) August 8, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the...
Incyte???s (INCY) late-stage study on tafasitamab for patients with relapsed or refractory follicular lymphoma meets its goal. FDA approves axatilimab...
Lyell Immunopharma, Inc, a clinical─stage T─cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid...
But what if a mouthwash-based test to detect biomarkers can help physicians predict disease recurrence in head and neck cancer patients?
Positive Phase 2a Fibromyalgia Results Deliver Pain Reduction in 100% of Patients, Strengthening IP Position and Clinical Trial Strategy Tryptamine...